GlassScriptPhysician profile
Elizabeth Jasarevski
NPI 1851831424
$4,836.50
in general payments reported to CMS, 2019-2025
33 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,569 · 2022: $1,325 · 2023: $1,083 · 2024: $692 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $646.75 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $578.04 | 2021-2024 | |
| Lilly USA, LLC | $451.63 | 2021-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $406.82 | 2021-2025 | Farxiga, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $304.68 | 2021-2024 | Trelegy Ellipta |
| Pfizer INC. | $304.01 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.17 | 2021-2024 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Abbott Laboratories | $190.61 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $159.98 | 2021-2024 | Otezla, Repatha |
| Janssen Biotech, INC. | $155.34 | 2021-2024 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.26 | 2021-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $136.87 | 2021-2024 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $133.02 | 2021-2023 | Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $120.67 | 2022 | |
| Antares Pharma, INC. | $102.82 | 2021-2023 | Nocdurna, Tlando, Xyosted |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $100.66 | 2021-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $83.89 | 2021-2022 | |
| Astellas Pharma US INC | $75.60 | 2022-2023 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $61.47 | 2021-2022 | |
| Exact Sciences Corporation | $56.88 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $51.11 | 2021 | |
| Theratechnologies INC. | $49.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.18 | 2021-2022 | |
| Amarin Pharma, INC. | $34.67 | 2021 | |
| Eisai INC. | $28.16 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.90 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $24.10 | 2023 | |
| Organon LLC | $19.29 | 2025 | Nexplanon |
| Esperion Therapeutics, INC. | $17.33 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.66 | 2022 | |
| Endo Pharmaceuticals INC. | $16.44 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.97 | 2022 | |
| Halozyme INC | $13.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Jasarevski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.